HPV and Cervical Cancer Risk
Author Information
Author(s): Sigstad E, Lie A K, Luostarinen T, Dillner J, Jellum E, Lehtinen M, Thoresen S, Abeler V
Primary Institution: The Norwegian Radium Hospital
Hypothesis
Is prediagnostic Human Papillomavirus seropositivity related to the presence of HPV DNA in subsequent cervical carcinomas?
Conclusion
Prediagnostic HPV seropositivity increases the risk of developing cervical carcinoma only if the carcinoma contains the same type of HPV DNA.
Supporting Evidence
- HPV16-seropositive women had a 4.4-fold increased risk of developing cervical carcinoma with HPV16 DNA.
- There was no excess risk for HPV16-seropositive women to develop carcinoma without HPV16 DNA.
- Prediagnostic HPV16 seropositivity was strongly correlated with later HPV16 DNA positivity in tumors.
Takeaway
Women who had HPV antibodies before getting cervical cancer were more likely to have cancer that also had HPV DNA in it.
Methodology
The study linked serum samples from women to cancer registries and analyzed HPV seropositivity and DNA presence in cervical tumors.
Potential Biases
Potential for misclassification of HPV status due to long storage times of serum samples.
Limitations
Some cases were excluded due to unconfirmed diagnoses or inability to retrieve tumor specimens.
Participant Demographics
Women from Norway, Finland, and Sweden, with a focus on those diagnosed with cervical carcinoma.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 2.2–8.8
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website